A large review looked at children with acute lymphoblastic leukemia who received fluoroquinolone antibiotics to prevent infections. The study compared those who took these drugs to those who did not during the start of their cancer treatment. Results showed a clear benefit for the group taking the medicine.
Children taking fluoroquinolones had about 56 percent fewer episodes of fever with low white blood cells. This is a major improvement because fever and low counts often mean serious trouble for young patients. The data also showed fewer bloodstream infections in the group that took the preventive antibiotics.
However, the study did not find a change in death rates or infections caused by a specific bacteria. These medicines were generally well tolerated with no major safety problems reported in the review. Doctors can use this information to help protect children from dangerous infections early in their care.
The main takeaway is that using these antibiotics helps reduce serious illness without increasing death risk. This approach may make the difficult cancer treatment easier for young patients to handle and survive.